The application of Vipassana in the treatment of depression: what the literature actually says

The shape of the evidence, in numbers

The honest summary of the published Vipassana-and-depression literature is small. Counting is the cleanest way to show why.

None of these counts are an argument against Vipassana. They are a precise account of what the published clinical literature on the technique, with depression as the question, currently holds. Saying the corpus is small is not saying the practice is ineffective; it is saying the gold-standard evidence has not been generated.

The two most-cited primary studies, side by side

Almost every article online that claims Vipassana reduces depression traces back, somewhere in its citation chain, to one of these two studies. Putting them next to each other makes the scope (and the limits) easier to see than reading either alone.

Both studies report a statistically significant drop in depression scores after a 10-day course. Both have the design limitations the authors disclosed in print: small samples, self-selection, environmental confounders (silence, simple food, sleep, no phones), and no clinical-population diagnosis at intake. Reading them as foundational rather than as definitive is the position consistent with what their own authors wrote.

What the Khosla five-case series adds

The Vipassana Research Institute hosts a paper by Dr. Raman Khosla titled Before and After: Five Case Studies of Improvement in Mental Health. It is a case series, not a trial, and it should be read as one. What it does offer is named instruments (Hamilton Depression Scale, Hardiness Index, Symptom Checklist, Ways of Coping Questionnaire) and pre/post numbers for five individuals across different presentations: alcohol dependence, depression, anxiety and panic, OCD, and borderline personality disorder.

A case series of five is not a basis for clinical recommendation. It is a record of what the technique looked like alongside other treatment changes in specific named individuals, written by an author affiliated with the tradition. The medication discontinuations in particular need to be read as descriptions of those specific cases under specific care, not as a generalizable pattern.

Why the bigger meta-analyses on meditation and depression do not settle this question

The body of clinical evidence for meditation broadly on depression is much larger than the Vipassana-specific evidence. The Jain et al. 2015 review, which is the most widely cited critical analysis of meditation therapies in acute and subacute phase depression, examined 18 trials with within-group effect sizes ranging from 0.93 to 3.33 in acute populations and 0.65 to 1.02 in subacute populations. Those numbers are encouraging.

The catch is what those 18 trials studied. They studied mindfulness-based cognitive therapy (MBCT, the bulk of the corpus), mindfulness-based stress reduction (MBSR), and a small number of other mixed mindfulness interventions. They did not study the Goenka 10-day Vipassana course. The review excluded it because no trial of that intervention in clinically diagnosed depression met its inclusion criteria. Citing the review's effect sizes as evidence that Vipassana works for depression is a category error: those effect sizes belong to a related but distinct family of interventions delivered in a different format by different practitioners over a different duration.

The 2025 Cureus review of 11 Vipassana-specific studies is the most recent attempt to summarize the technique on its own. Saxena and colleagues report moderate evidence across psychological, physiological, and behavioural domains (anxiety, stress, mindfulness, well-being, heart rate variability, hippocampal topology, executive function), with heterogeneity precluding meta-analysis. Depression as a primary, separately-analyzed outcome is not in their narrative. That absence is the gap the keyword surfaces.

What the tradition itself does and does not claim

The Goenka tradition does not market the 10-day course as a depression treatment. The application form has a long psychiatric history section (anxiety, panic, manic depression, schizophrenia, hospitalization history, medication, present condition). Applicants disclosing acute or unstable conditions may be deferred. The standard guidance is to continue prescribed medication; the tradition explicitly does not ask attendees to stop. Assistant teachers, who run the course, are trained volunteers, not clinicians.

For anything operational about practice, posture, sensation, duration, or how to work with a difficulty on the cushion, the redirect across this entire site is the same: go to dhamma.org and to an authorized assistant teacher inside a 10-day residential course. This page is a literature note about how a research-flavoured query maps onto the published evidence base. It is not practice instruction and it is not clinical advice.

What I have noticed across 0 ten-day courses

I am not a teacher and not a clinician, just a long-time student. Across six 10-day courses at three centres (Dhammamanda in NorCal, CYO in the Bay Area, North Fork in Central California), and across roughly 40 days of dhamma service volunteering at courses, the pattern I have personally observed in students disclosing a history of depression has been consistent with what the literature implies, not with stronger claims. Students with managed, stable depression typically complete the course; some describe the experience as useful in changing the relationship to depressive states over time. Students in an acute episode are advised, and sometimes decide, to defer. Nobody at any of those centres has ever told a student that the course will treat their depression. The language used is general practice training, not clinical intervention. That gap between language and clinical claim is doing real work.

None of this is data, only observation. The reason it sits in its own section, clearly labelled, is that other pages tend to blur observation and evidence into a single softer claim. The two are different and deserve to be kept apart.

For anyone who arrived at this page looking for a decision, not a literature review

If the question behind your search is whether to attend a 10-day course while living with depression, the page on this site that is actually written for that question is Vipassana and Depression. It covers when attending is generally fine, when to wait, what the post-course period can look like, and how the practice sits alongside professional care. If your question is whether to stop or continue prescribed medication for a course, that conversation belongs with your treating clinician and the course management team, in that order, not with any web page.

If you want to be matched with another practitioner for daily accountability after a course, the practice buddy programme pairs old students for short daily sits over a video call. It is peer support, not therapy, and is appropriate when the depression piece is being held by someone qualified to hold it.